Vantage logo

Zantac burns big pharma

As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?

Vantage logo

Amarin falls at obvious hurdle

Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.